Pre-operative Administration of Sorafenib in Patients With Metastatic Renal Cell Carcinoma Undergoing Kidney Removal
Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if preoperative administration of Sorafenib reduces the
size of the primary kidney tumour in patients with metastatic disease undergoing
cytoreductive surgery.
The study will also assess the safety of preoperative Sorafenib.
The study drug, Sorafenib, will be given to patients preoperatively for 12 weeks. After a 1
week washout period the patient will then have their nephrectomy (kidney removed).
Approximately 6 weeks following their nephrectomy, patients will resume on study drug until
disease progression.